Hepagene Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for HPG7233 THR Beta Agonist
- Written by PR Newswire
HONG KONG and NANJING, China, Sept. 20, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its HPG7233, an agonist of Thyroid Hormone Receptor beta (THR-β) for the treatment...














